ATH Share Price Performance
AU$0.008
-0.00 (-5.88%)
Price AU$0.008
Share Pricen/a
Alterity Therapeutics Limited Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 6 Fair Values set on narratives written by author
ATH Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Alterity Therapeutics Limited Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -0.0011
- 97.66%
- -223.35%
- 0%
About ATH
- Founded
- 1997
- Employees
- 9
- CEO
- WebsiteView website
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
